Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma in India

  • Rahul Naithani
  • Nitin Dayal
  • Reeta Rai
  • Sangeeta Pathak
  • Manoj Singh
Correspondence
  • 7 Downloads

Notes

Compliance with Ethical Standards

Conflict of interest

The author declares that they have no conflict of interest.

Ethical Approval

The study was approved by Institutes’ Ethics Committee.

References

  1. 1.
    Kumar L, Boya RR, Pai R et al (2016) Autologous stem cell transplantation for multiple myeloma: long-term results. Natl Med J India 29(4):192–199PubMedGoogle Scholar
  2. 2.
    Malhotra P, Yanamandra U, Khadwal A et al (2017) Autologous stem cell transplantation for multiple myeloma: single centre experience from North India. Indian J Hematol Blood Transfus.  https://doi.org/10.1007/s12288-017-0876-y Google Scholar
  3. 3.
    Naithani R, Dayal N, Dixit G (2017) Single versus dual platform analysis for hematopoietic stem cell enumeration using ISHAGE protocol. Indian J Hematol Blood Transfus 33(3):370–374CrossRefPubMedGoogle Scholar
  4. 4.
    Prinja S, Kaur G, Malhotra P et al (2017) Cost-effectiveness of autologous stem cell treatment as compared to conventional chemotherapy for treatment of multiple myeloma in India. Indian J Hematol Blood Transfus 33(1):31–40CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Kumar R, Kapoor R, Asthana B et al (2017) Single dose preemptive plerixafor for stem cell mobilization for ASCT after lenalidomide based therapy in multiple myeloma: impact in resource limited setting. Indian J Hematol Blood Transfus 33(4):463–469CrossRefPubMedGoogle Scholar

Copyright information

© Indian Society of Hematology and Blood Transfusion 2018

Authors and Affiliations

  1. 1.Division of Hematology and Bone Marrow TransplantationMax Superspeciality HospitalNew DelhiIndia
  2. 2.Department of Lab MedicinesMax Superspeciality HospitalNew DelhiIndia
  3. 3.Department of Transfusion MedicineMax Superspeciality HospitalNew DelhiIndia

Personalised recommendations